Posted by Michael Wonder on 13 Apr 2023
Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say
13 April 2023 - If courts affirm US District Judge Matthew Kacsmaryk’s decision to suspend the FDA’s approval, it could make way for more lawsuits challenging the agency’s decision-making related to existing and future drugs.
A messy legal fight over the FDA’s approval of the abortion pill mifepristone poses risks to the biopharma industry that go beyond the single drug.
